product name: vildagliptin
synonyms: pharma api vildagliptin;vildagliptin api;2-pyrrolidinecarbonitrile,1-[2-[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2s)-;vildagliptin (-)-(2s)-1-[[(3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)amino]acetyl]pyrrolidine-2-carbonitrile;1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(s)-pyrrolidine;vildaliptin;vildagliptin (nvp-laf 237);vildagliptin, 97%, dpp-4 inhibitor
cas: 274901-16-5
mf: c16h15f6n5o h3o4p h2o
mw: 303.4
einecs: 630-410-0
melting point 153-155 c
alpha -78.3° (c = 9.73 in methanol)
boiling point 531.3±50.0 °c(predicted)
density 1.27
fp 275.1℃
hs code 29339900
uses the major metabolite of vildagliptin
uses labelled vildagliptin. it is a new oral anti-hyperglycemic agent of a new dipeptidyl peptidase-iv (dpp-iv) inhibitor class of drugs. antidiabetic.

vildagliptin, a dpp-4 inhibitor, was launched for the oral treatment of type 2 diabetes. vildagliptin is the second dpp-4 inhibitor to reach the market behind sitagliptin, which was introduced in 2006. dpp-4 inhibitors act by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. when blood glucose concentrations are normal or elevated, glp-1 and gip increase the synthesis and release of insulin from pancreatic βcells via intracellular signaling pathways involving camp. glp-1 also lowers glucagon secretion from pancreatic α cells, which leads to reduced hepatic glucose production. however, although glp-1 and gip effectively lower blood glucose, they are short-lived as a result of rapid inactivation by the ubiquitous serine protease dpp-4. by inhibiting dpp-4, vildagliptin increases the concentration and duration of active incretin levels, which in turn results in increased insulin release and decreased glucagon levels in a glucose-dependent manner. both vildagliptin and sitagliptin are potent, competitive, reversible inhibitors of dpp- 4 (ic50=3.5 and 18 nm, respectively), and they both show slow, tight-binding inhibition kinetics.